Our governance structure has been established to address the evolving genomic landscape, and to reflect the broad portfolio of genomic technologies in health.
The governance model enables consultation with a wide range of stakeholders, from consumers and the community, through to industry, government, and international genomic endeavours.
Independent Advisory Board
Chaired by Prof Brian Schmidt, Vice Chancellor and President of The Australian National University, our Independent Advisory Board advises on Australian Genomics activity and facilitates the implementation and uptake of Australian Genomics outcomes in consideration of industry, healthcare, academia and government policy.
View committee
- Prof Brian Schmidt AC (Chair), Australian National University
- John Brumby AO, La Trobe University
- Dame Quentin Bryce AD, CVO, 25th Governor General of Australia
- Prof Tom Calma AO, Poche Indigenous Health Network
- Bronwyn Field, Department of Health
- Prof Ian Frazer AC, University of Queensland
- Jane Halton AO PSM, COTA Australia
- Peter Yates AM, AIA Australia Limited, Linfox Australia Pty Ltd
National Steering Committee
Our National Steering Committee is made up of the leads of our Grant Program, each applying their expertise across the research priorities of Australian Genomics. With shared national leadership, the committee monitors the progress of our work and drives the scientific strategy, engagement, coordination and coherence of Australian Genomics.
View committee
- Prof Kathryn North, Murdoch Children’s Research Institute (Chair)
- Tiffany Boughtwood, Australian Genomics
- Prof Jeffrey Braithwaite, Macquarie University
- Prof Alex Brown, South Australian Health and Medical Research Institute
- Prof John Christodoulou, Murdoch Children’s Research Institute
- Prof Sally Dunwoodie, Victor Chang Cardiac Research Institute
- Prof Clara Gaff, Melbourne Genomics Health Alliance
- Prof Julie McGaughran, Genetic Health Queensland
- Prof Jozef Gecz, The University of Adelaide
- Prof Oliver Hofmann, The University of Melbourne
- Prof Emma Kowal, Deakin University
- Dr Daniel MacArthur, Garvan Institute of Medical Research & Murdoch Children’s Research Institute
- Dr Cliff Meldrum, NSW Health Pathology
- Sean Murray, Mito Foundation
- Prof Ainsley Newson, The University of Sydney
- Dr Kristen Nowak, WA Health, Government of Western Australia
- Prof Hamish Scott, SA Pathology
- Prof Amanda Spurdle, QIMR Berghofer Medical Research Institute
- Prof Zornitza Stark, Victorian Clinical Genetics Services
- Prof Robyn Ward, The University of Sydney
National Implementation Committee
The National Implementation Committee is chaired by the Australian Government Department of Health and serves as a forum for guidance, consultation and cross communication across Australian Genomics, governments and other agencies and organisations. Members include those from State, Territory and Federal Governments, the Medical Services Advisory Committee, the CSIRO and the Pharmaceutical Benefits Advisory Committee. The Committee enables a two-way dialogue on real world challenges in genomic medicine implementation across jurisdictions and consideration of how research might best be directed to bring clarity to these challenges.
View committee
- Bronwyn Field, The Australian Government Department of Health (Chair)
- Dr Paul Fennessy, Department of Health Victoria
- Dr Rob Grenfell, CSIRO
- Dr Tristan Hardy, SA Pathology
- Dr Nigel Lyons, NSW Ministry of Health
- Prof Keith McNeil, Queensland Health
- Dr Kristen Nowak, WA Health, Government of Western Australia
- Mr Alan Philp, ACT Health
- Dr Madhivanan Sundaram, Top End Health Service, NT Health
- Dr Mathew Wallis, Tasmanian Health Service
- Prof Robyn Ward, Medical Services Advisory Committee
- Prof Andrew Wilson, Pharmaceutical Benefits Advisory Committee
- Tiffany Boughtwood, Australian Genomics
- Prof John Christodoulou, Murdoch Children’s Research Institute
- Prof Clara Gaff, Melbourne Genomics Health Alliance
- Prof Kathryn North, Murdoch Children’s Research Institute
International Advisors
The advisors bring international best practice to our work and provide opportunities for international collaboration. They include representatives of the Global Alliance for Genomics and Health (GA4GH), the GA4GH Genomics in Health Implementation Forum, the Global Genomic Medicine Collaborative (G2MC), Genomics England, GEM Japan, Broad Institute, Canadian Institute of Health Research and H3Africa Bionet.
Community Advisory Group
The Community Advisory Group brings together experienced patient advocates providing counsel on our research activity. The Group advises on the design and language of patient surveys, digital health and data management strategy, and ethical, legal and social analyses of genomics.
View committee
- Sean Murray, Mito Foundation (Chair)
- Jessica Bean, Patient advocate
- John Cannings, Patient advocate
- Rachael Casella, Patient advocate
- Richard Vines, Rare Cancers Australia
- Kathy Wells, Breast Cancer Network of Australia
- Tiffany Boughtwood, Australian Genomics
- Prof John Christodoulou, Murdoch Children’s Research Institute
- Prof Martin Delatycki, Victorian Clinical Genetics Services
Aboriginal and Torres Strait Islander Advisory Group
The Aboriginal and Torres Strait Islander peoples genomic advisory group was formed by the Australian Government’s Department of Health. Committee members identify key issues impacting health access for Aboriginal and Torres Strait Islander peoples and research in terms of the clinical application of genomics. The Group will provide Australian Genomics with advice on its research priorities and engagement of the community.
Industry Advisory Group
The Industry Genomics Network Alliance (InGeNA) was formed in late 2020 to strengthen collaboration, coordinate on key issues and realise opportunities for all Australians to benefit from precision healthcare. The companies who founded InGeNA under the auspices of the Australasian Institute of Digital Health will collaborate on programs to embed genomics across Australian healthcare. Companies representing pathology, technology and biopharma sectors, contributed funding to start InGeNA matched by MTPConnect’s Industry Growth Centre Project Fund Program.